Semaglutide dissolving microneedle patch

A July 2026 paper in AAPS PharmSciTech describes a dissolving microneedle patch that uses L-arginine as an excipient to stabilise semaglutide during transdermal delivery^[1]. The work is early-stage and preclinical, but it addresses a real constraint: oral semaglutide (Rybelsus) has a published comparative bioavailability of around 0.66% relative to the subcutaneous route^[2], and weekly injection remains the dominant delivery method for the weight-loss and diabetes indications.

What the researchers built

The team at Wayne State University and Brooklyn College of Pharmacy combined hyaluronic acid, PETOX polymer, and L-arginine into a dissolving microneedle (DMN) matrix^[1]. The needles are designed to pierce the outer skin layer, dissolve on contact with interstitial fluid, and release semaglutide into the dermis without the mechanical complexity of an autoinjector pen. The L-arginine component is doing two jobs: it raises the local pH to a range that reduces peptide aggregation, and it interacts with semaglutide's fatty-acid side chain in a way that slows enzymatic degradation.

The measured fracture force was 3.47 N per needle, which is the load threshold the field typically cites for reliable skin insertion. Parafilm M penetration testing (a standard proxy for stratum corneum resistance) showed greater than 50% insertion depth at 450 micrometres. Drug release extended over 12 hours in vitro. Fluorescence imaging confirmed that the payload did reach transdermal depths, which is the proof-of-concept step the authors were aiming for.

Why the L-arginine finding matters

Prior microneedle work for peptide drugs has mostly focused on mechanical performance and drug loading. The authors describe this as the first systematic investigation of L-arginine specifically as a peptide-stabilising excipient in a dissolving microneedle matrix^[1]. That is a narrow but defensible claim: the literature has used L-arginine as a solubiliser and aggregation inhibitor in parenteral formulations, but applying it in a dissolving polymer matrix designed to sit against skin for minutes is a different context.

Semaglutide's structure makes stability a genuine challenge outside a controlled injectable. It is a 31-amino-acid GLP-1 analogue with a C18 fatty-acid chain and two site-specific substitutions (at positions 8 and 34) that extend its half-life in the subcutaneous compartment to around a week. But in a solid matrix exposed to skin temperature, moisture, and mechanical shear, that fatty-acid chain can promote fibril formation. L-arginine's guanidinium group appears to interrupt that process.

What the paper does not establish

This is a formulation study, not a pharmacokinetic or efficacy trial. The paper reports in vitro drug release and fluorescence skin-penetration imaging. There are no plasma drug-level data, no glucose or body-weight outcomes, and no comparison to the subcutaneous product. The authors also tested a single semaglutide loading level across a single matrix composition, so dose-response relationships within the patch format remain uncharacterised.

A 2025 paper from Inha University tested a comparable concept: hyaluronic acid and aminoclay nanocomposite microneedles for semaglutide in type-2 diabetic rats^[3]. That study did include in vivo data and found efficacy comparable to subcutaneous injection on glucose and body-weight endpoints after 30 days of daily administration. The Wayne State / Brooklyn College work does not build on those in vivo results directly, but the two papers together suggest the transdermal route is reproducibly reaching the tissue layer that matters, at least in preclinical conditions.

The patient compliance angle

The authors frame the work around three practical problems: low oral bioavailability, injection-related discomfort, and adherence. Semaglutide's oral form addresses the first of those at a significant bioavailability cost^[2]. Weekly subcutaneous injection handles the bioavailability problem but keeps the needle, the cold-chain requirement, and the potential for injection-site reactions. A dissolving patch that achieves therapeutic drug levels without a needle would, in principle, reduce all three barriers.

Whether a patch format can reach the plasma concentrations that the approved subcutaneous semaglutide products (Ozempic for diabetes, Wegovy for obesity) achieve at their maintenance doses is an open question. The subcutaneous products deliver precise weekly doses with well-characterised pharmacokinetics. A patch would need to demonstrate bioequivalence in humans before any regulatory filing would be possible, and no timeline for that work has been disclosed in connection with this paper.

Where this fits in the semaglutide delivery landscape

The approved oral form (Rybelsus) uses the SNAC absorption enhancer and requires fasting administration. It tops out at a 14 mg daily dose for type-2 diabetes and has not been approved for weight management at the oral dose strengths. The subcutaneous forms scale to 2.4 mg weekly for obesity (Wegovy). A transdermal format would need to sit somewhere in that pharmacokinetic space to be clinically useful, and the engineering distance between a proof-of-concept fluorescence image and a Phase 1 trial is considerable.

For readers following the development of semaglutide delivery formats, this paper is a data point in a longer arc. The AAPS PharmSciTech finding is the kind of formulation result that precedes rather than predicts clinical translation. We will continue to track transdermal and non-injectable approaches as they reach pharmacokinetic or efficacy stages.